spacer
home > pmps > spring 2017 > manufacturing a renaissance
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Manufacturing a Renaissance

The pharmaceutical industry is proud of its technical innovations in the discovery and development of new medicines, and rightly so – for example, the discovery of penicillin and its development as a drug product revolutionised the treatment of infectious diseases. But the pharma industry has sadly fallen far behind in product manufacturing efficiency and innovation. The polymer and foods sectors especially are constantly driving continuous improvement in manufacturing efficiencies, whereas pharma manufacturing practices have not changed significantly in fifty years.

This inertia has been attributed to constraints by regulatory agencies in what are deemed acceptable manufacturing and quality control practices. Batch processing continues to be the normal practice for medicinal products, due to the visibility and control over quality critical factors such as ingredient lots used and processing parameters. However, things are changing.

Implementation of Quality by Design (QbD) principles in product development is resulting in greater emphasis being placed on demonstrating process control through the monitoring of critical process parameters to confirm satisfactory product quality, instead of relying on the traditional approach of the testing of stratified samples. This approach is now considered as ‘best practice’ by regulatory agencies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Robert Harris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Announces Executive Leadership Transition


More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

 
Industry Events

Pharma and Device Packaging and Labeling West Coast 2017

28-29 November 2017, Burlingame, California

Following a very successful launch year, we are thrilled to announce that Pharma and Device Packaging and Labeling will be returning to the West Coast for our 2nd annual event.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement